U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s …
WEBApr 5, 2024 · Abecma is now approved in the U.S., Japan, Switzerland and the EU for earlier use for triple-class exposed relapsed and/or refractory multiple myeloma, underscoring BMS’ commitment to delivering Abecma globally, with consistently high manufacturing success rates and continuous increases in capacity.
FDA Approves First Cell-Based Gene Therapy for Adult Patients …
WEBMar 27, 2021 · The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose...
Citing enrollment challenges, Bristol Myers and 2seventy scrap …
WEB2 days ago · Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. Bristol and its partner 2seventy bio have decided to pull the plug on the phase 3 KarMMa-9 trial. The trial had ...
Bristol Myers Squibb - Bristol Myers Squibb’s Abecma …
WEBMar 20, 2024 · Bristol Myers Squibb assumes sole responsibility for Abecma drug product manufacturing and commercialization outside of the U.S. The companies’ broad clinical development program for Abecma includes ongoing and planned clinical studies (KarMMa-2, KarMMa-9) for patients with multiple myeloma.
Bristol Myers Squibb - U.S. Food and Drug Administration …
WEBMar 26, 2021 · Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma1. In the pivotal KarMMa trial, the majority (72%) of patients achieved rapid, deep and …
FDA Approves Abecma for RRMM | Int'l Myeloma Foundation
WEBApr 5, 2024 · This press release covers the FDA-approval of Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy.
FDA approves BMS' multiple myeloma CAR-T Abecma
WEBSep 19, 2024 · The FDA has approved Bristol-Myers Squibb’s Abecma (idecabtagene vicleucel) for multiple myeloma, the first cell therapy to treat the disease.
FDA Approves Ide-Cel for Triple-Class Exposed R/R Multiple
WEBApr 5, 2024 · The FDA has approved idecabtagene vicleucel (ide-cel; Abecma) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy,...
2seventy bio Provides Update on KarMMa-9 Study and Previews …
WEB2 days ago · Early deaths occurred in 8% (20/254) and 0% prior to ABECMA infusion and standard regimen administration, respectively, and 10% (25/254) and 11% (15/132) after ABECMA infusion and standard regimen ...
ABECMA (idecabtagene vicleucel) | FDA
WEBApr 21, 2021 · ABECMA is the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapies including an immunomodulatory agent, a proteasome...
Skip to content